By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Atossa Genetics today filed a preliminary prospectus with the US Securities and Exchange Commission to raise up to $17.6 million from an initial public offering.

Proceeds from the offering will be used to create a cytology and molecular diagnostics laboratory focused on breast cancer, and to manufacture and launch its FDA-cleared Mammary Aspirate Specimen Cytology Test System in the Northwestern US, the Seattle-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.